Tirzepatide, 10mg

Product Category

Dual Incretin Mimetics, GIP/GLP-1 Receptor Agonists & Advanced Weight Management Peptides

Action on the Human Body

Tirzepatide is a synthetic 39-amino acid linear peptide engineered with a C20 fatty diacid moiety that enables once-weekly pharmacokinetics via albumin binding. It acts as a dual agonist at both Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) receptors. By combining these vectors, Tirzepatide delivers unmatched metabolic modification: its GIP receptor activity elevates insulin efficiency and controls nausea indicators, while its GLP-1 activity delays gastric clearance and triggers profound satiety networks within hindbrain pathways. This dual configuration accelerates lipolysis, halts adipocyte storage, and maximizes full-body fat reduction.

What to Expect if Consumed

Users report a total cessation of intense food cravings, substantial reductions in visceral and subcutaneous fat depots, and stable, day-long glycemic balance with zero energy crashes.

Possible Therapy Combinations

Pairs perfectly with 5-Amino-1MQ to drive an intense metabolic and cellular fat reduction phase, or stacked with BPC-157 to preserve total digestive tract layout and gastric comfort.

Molecular Formula & Chemical Composition

Sequence: 39-amino acid conjugated lipid backbone structure. Molecular Formula: C225H348N48O68. Purity: >99% Pure Lyophilized Form via strict HPLC analytical testing.

WARNING: This peptide compound must be handled and utilized exclusively under very high, correct professional and qualified medical supervision. Misuse can lead to unintended biological variations.

Scientific References

1. Jastreboff, A. M., et al. (2022). ‘Tirzepatide once weekly for the treatment of obesity.’ New England Journal of Medicine.
2. Frias, J. P., et al. (2021). ‘Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes.’ New England Journal of Medicine.